Meningitis B Vaccine for Adults in the UK: Who Should Get Vaccinated and How
Medically reviewed by The Online GP by The Wellness Medical Team — Last updated: 21 March 2026
Adults of any age can get the meningitis B vaccine (Bexsero) privately in the UK — there is no upper age limit. The vaccine is not routinely offered to adults on the NHS, which means almost every adult in the country is unvaccinated against MenB, the most common cause of bacterial meningitis in the UK. While the highest risk is in infants and young adults aged 15–24, meningococcal disease can and does affect older adults. Following the 2026 Kent outbreak, many adults are reassessing their own protection — and with good reason. Here is everything you need to know to make an informed decision.
Discuss Your Options With a Doctor — WhatsApp → | Email: team@thewellnesslondon.com
The Facts: Adult Meningitis Risk in the UK
The risk of meningococcal disease is not evenly distributed across age groups. Infants under 1 year face the highest incidence, followed by adolescents and young adults aged 15–24. After age 25, the risk drops — but it does not disappear. In the UK, approximately 378 cases of invasive meningococcal disease were confirmed in 2024–25, with 31 deaths. While the majority of cases affect younger age groups, adults over 25 account for a meaningful proportion of cases nationally. Adults with certain medical conditions face a substantially elevated risk regardless of age, and sporadic cases occur across all age groups throughout the year. The case fatality rate of 8–15% and the devastating disability rate of up to 20% among survivors apply equally to adults as to younger patients. Meningococcal disease does not become less dangerous with age — if anything, diagnosis can be delayed in older adults because clinicians may not immediately consider meningitis in an older patient presenting with fever and confusion.
Which Adults Should Most Strongly Consider Vaccination
While any unvaccinated adult can benefit from MenB protection, certain groups have a stronger case for vaccination based on their risk profile. Healthcare workers who come into contact with patients, particularly in emergency departments, intensive care, or microbiology laboratories, face occupational exposure to meningococcal bacteria. Vaccination adds a layer of personal protection on top of standard infection control measures. Adults in shared or communal accommodation — including house-shares, military barracks, and residential care settings — face elevated risk due to the prolonged close contact inherent in these living arrangements. If you share a kitchen, bathroom, and living space with multiple people, your exposure risk is higher than someone living alone or with a partner. Travellers to endemic regions — particularly sub-Saharan Africa's "meningitis belt" stretching from Senegal to Ethiopia — may need meningococcal vaccination as part of their travel health preparation. MenACWY is the primary travel vaccine for this region, but MenB may also be advisable depending on your itinerary and the local epidemiology. People with specific medical conditions including asplenia (absent or non-functioning spleen), sickle cell disease, complement deficiency disorders, those on complement inhibitor therapy (such as eculizumab), and those with other forms of immunosuppression. If you have any of these conditions, you should be eligible for free NHS MenB vaccination — speak to your GP. If you have not been vaccinated despite being eligible, do so urgently. Parents of young children may wish to be vaccinated to reduce the theoretical risk of household transmission. While the primary risk to infants comes from other children and teenagers (who have the highest carriage rates), parental vaccination adds another layer of protection to the household. Adults who simply want comprehensive protection against a devastating disease for which they are currently unvaccinated. This is a legitimate and proportionate health decision, even in the absence of specific risk factors.
How the Vaccine Works in Adults
Bexsero has been clinically tested in adults and university-aged students. A Phase 3 study involving 974 university students aged 18–24 at UK universities confirmed that two doses of Bexsero produce a robust immune response, with the majority of participants developing protective bactericidal antibodies against the vaccine antigens. The vaccine works by stimulating the immune system to recognise four key proteins on the surface of MenB bacteria. Unlike earlier meningococcal vaccines that targeted the polysaccharide coating, Bexsero uses recombinant protein technology — necessary because the MenB outer surface resembles human tissue and evades traditional immune recognition. Adults require two doses, given at least one month apart. The optimal schedule for maximum long-term protection is doses at 0 and 6 months. If faster protection is needed, the three-dose schedule (0, 1–2, and 6 months) is available. Some protection begins after the first dose, but two doses are needed for the full immune response. Current evidence suggests protection lasts at least 3 years after the two-dose course, though long-term duration in adults is still being studied. Your doctor at The Online GP by The Wellness can advise on whether a booster may be appropriate in future based on your individual risk profile.
The Licensing Position: No Upper Age Limit in the UK
There is occasional confusion about age limits for Bexsero, partly because different countries have different licensing arrangements. In the UK, Bexsero is licensed by the European Medicines Agency for use in individuals aged 2 months and older, with no specified upper age limit. This means adults of 30, 40, 50, 60, or any age can be vaccinated in the UK. In the United States, the FDA approval covers ages 10–25, but this restriction does not apply in Europe or the UK. The reason younger age groups are prioritised is not that the vaccine is ineffective in older adults — it is that the highest disease incidence is in babies and young adults, so public health programmes focus resources where the greatest impact can be achieved. For individual adults who wish to be vaccinated, the option is available privately without age restriction.
Join the MenB Waiting List — WhatsApp →
Cost and Availability for Adults
Under normal market conditions, private MenB vaccination for adults costs £100–195 per dose depending on the provider, with the full two-dose course ranging from £200–390. During the current national shortage, prices are higher. This reflects the genuine reality that clinics are paying upwards of £300–400 per dose at procurement level during the shortage — standard wholesale channels have been largely exhausted. We are transparent about this and will adjust pricing downwards as supply normalises. We are currently operating a waiting list for MenB vaccination. Contact us on WhatsApp at +44 7961 280835 or email team@thewellnesslondon.com to register your interest. We will notify you as soon as stock becomes available. While waiting for MenB, consider whether you also need MenACWY (which covers four additional strains and may be available immediately), travel vaccines if you have upcoming international travel, or a comprehensive vaccination review to identify any other gaps in your protection. Our same-day GP appointments are available from £49 (phone), £79 (in-person), or £150 (video) for any health concern — not just vaccination.
Register for Waiting List — WhatsApp →Book a Same-Day GP Appointment — WhatsApp → Email: team@thewellnesslondon.com
Frequently Asked Questions
Can adults get the meningitis B vaccine? Yes. Bexsero has no upper age limit in the UK. Adults of any age can be vaccinated privately. Two doses are needed, given at least one month apart.
Should I get vaccinated if I am over 25? If you have risk factors (healthcare work, shared accommodation, travel, medical conditions), vaccination is strongly worth considering. Even without specific risk factors, the devastating nature of meningococcal disease makes vaccination a proportionate choice for any unvaccinated adult.
Is the vaccine effective in adults? Yes. Clinical trials in university-aged students confirmed robust immune responses. Bexsero covers approximately 88% of MenB strains in the UK. Protection lasts at least 3 years.
How much does it cost? Currently expect two or three times the normal rate reflecting the national shortage. Under normal conditions, £200–295/dose.
Is there an age limit? No upper age limit in the UK. The European licence covers 2 months and older without restriction.
Do I need it if I already had meningitis? Possibly — your previous infection may have been a different strain or organism. Vaccination is still recommended. Discuss your history with a doctor.
Where can I get it? The Online GP by The Wellness, Marylebone, London. Currently on waiting list. Register on WhatsApp (+44 7961 280835) or email team@thewellnesslondon.com. No NHS registration required.
The Online GP by The Wellness provides private doctor-led healthcare from our Marylebone clinic. All vaccinations are administered by GMC-registered doctors. Contact us on WhatsApp at +44 7961 280835 or email team@thewellnesslondon.com.UKHSA advises the risk to the wider public remains low. If you suspect meningitis symptoms, call 999 immediately.
References
UKHSA. Cases of invasive meningococcal disease confirmed in Kent. GOV.UK. Updated 21 March 2026.
European Medicines Agency. Bexsero EPAR — immunogenicity data in adults. Updated 2025.
GSK. Bexsero Summary of Product Characteristics. Electronic Medicines Compendium. 2025.
UKHSA. Invasive meningococcal disease in England: annual laboratory-confirmed reports. 2025.
Meningitis Now. FAQs on the MenB vaccine (Bexsero). Updated 2026.
FDA. Bexsero prescribing information — clinical trial data in adolescents and adults. 2024.
